Revenue segments as reported by the company.

Product revenues, net

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development expenses

Acquired in-process research and development expenses

Selling, general and administrative expenses

Change in fair value of contingent consideration

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Vertex Pharmaceuticals

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vertex Pharmaceuticals reports robust earnings, eyes growth in diverse therapies

Vertex Pharmaceuticals delivered strong financial results, provided optimistic revenue guidance for 2023, and emphasized investments in R&D and commercial capabilities. The company faces challenges with escalating costs and the need for clearer long-term financial goals. However, Vertex remains well-positioned to capitalize on growth opportunities in the healthcare market.

Vertex Pharmaceuticals reports robust Q1 growth and innovative pipeline

Vertex Pharmaceuticals had a strong Q1 2023 performance with revenue growth and ongoing investments in innovative therapies.
The company faces challenges in managing operating expenses and ensuring successful launches amidst competitive pressures.
However, Vertex's strengths lie in its diverse pipeline, regulatory approvals, and focus on transformative therapies.
Opportunities exist in addressing unmet medical needs, pursuing revenue growth in pain relief markets, and advancing non-opioid treatments.

Vertex Pharmaceuticals reports robust Q2 growth and pipeline advancements

Vertex Pharmaceuticals showed strong revenue growth and pipeline progress.
Challenges include slower uptake for gene therapies and market access.
Opportunities lie in reimbursement models, new therapy launches, and program advancements.
Overall, Vertex is strategically positioned for growth and innovation.

Vertex Pharmaceuticals reports strong Q3 growth and pipeline optimism

Vertex Pharmaceuticals shows solid financial performance and a robust pipeline of innovative therapies.
Challenges include navigating patient complexities, regulatory reviews, and market differentiation.
Opportunities lie in market expansion, therapeutic advancements, and strategic growth initiatives.
Overall, Vertex's focus on autonomy, innovation, and financial strength positions it for future success.

Vertex Pharmaceuticals reports robust Q4 earnings and strategic advancements

Vertex Pharmaceuticals delivered a strong performance in Q4 2023, driven by revenue growth, positive trial outcomes, and strategic advancements in its pipeline.
The company's focus on commercial diversification, regulatory approvals, and upcoming milestones in 2024 position Vertex well for continued success and growth.
While facing challenges related to patient targeting, physician capacity, and market differentiation, Vertex has opportunities to innovate, expand its reach, and enhance market positioning.
Overall, Vertex Pharmaceuticals' 2023 achievements, financial strength, and strategic initiatives underscore a promising outlook for the company's future growth and success.

Vertex Pharmaceuticals reports strong Q1 earnings and pipeline advancements

Vertex Pharmaceuticals demonstrated robust financial performance and strategic advancements in its pipeline and acquisitions, positioning itself for continued growth.
While facing challenges in commercialization and policy landscape, Vertex's strong financial position and innovative capabilities provide a solid foundation for future success.
With a focus on rare diseases, pain management, and revenue diversification, Vertex is poised to capitalize on market opportunities and drive innovation in healthcare.

Vertex Pharmaceuticals delivered strong revenue growth driven by key product demand, while facing increased operating expenses.
The company is focused on expanding its pipeline and accelerating new therapy launches amidst regulatory and commercial challenges.
Anticipation is high for upcoming launches like vanzacaftor and suzetrigine, signaling potential growth opportunities for Vertex.

Vertex Pharmaceuticals excels in Q3, poised for innovative growth

Vertex Pharmaceuticals demonstrated robust financial performance, highlighted by revenue growth and promising early launches. The company's strong R&D pipeline and strategic focus on commercialization underscore its commitment to driving innovation and growth. Addressing analyst inquiries and seizing growth opportunities will be key for Vertex's continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

The French reimbursement for Vertex's (VRTX) cystic fibrosis medicine Orkambi removes a key overhang for the stock.

Vertex (VRTX) Gets French Reimbursement for CF Drug Orkambi

As of late, it has definitely been a great time to be an investor Vertex Pharmaceuticals.

Vertex Pharmaceuticals Shares March Higher, Can It Continue?

Knight-Swift Transportation Holdings

Lumentum Holdings

Sherwin-Williams

Growth is on a different track now, and here are some great ideas for stocks to buy to ride the momentum.

Check Out These 5 Fast-Growing Stocks to Buy

CRISPR Therapeutics

Vertex (VRTX) and partner CRISPR Therapeutics announce positive early data from two studies on gene-editing drug CTX001 for the treatment of beta-thalassemia and sickle cell disease.

Vertex, CRISPR's Gene Editing Drug Shows Positive Early Data

Alexion Pharma

Incyte

Regeneron Pharmaceuticals

We highlight a few principal players from the biotech sector, which are likely to witness a winning run in the near term.

4 Big Biotech Stocks Worth Considering Post Q3 Earnings

Vertex Pharmaceuticals Is A Strong Buy

Vertex Pharmaceuticals (NASDAQ: VRTX) is an American biopharmaceutical company mainly focused on developing and commercializing therapies for the treatment of cystic fibrosis. Vertex has seen its stock price rise 15% over the last month, driven in part by the U.S.

Drug Approvals, Upbeat Earnings Help Vertex Pharmaceuticals’ Stock Jump 20% In A Month

-Molecular Templates to receive $38 million upfront payment, including equity investment, with potential for additional milestone and royalty payments on future sales-

Vertex and Molecular Templates Establish Collaboration to Discover and Develop Novel Targeted Conditioning Regimens to Enhance Hematopoietic Stem Cell Transplants

The Best Biotech Stock to Buy Right Now

Vertex (VRTX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Earnings Estimates Rising for Vertex (VRTX): Will It Gain?

Join The Vertex Energy Journey

Vertex: A Crown Jewel Of Biotech

Vertex Energy, Inc. (VTNR) CEO Benjamin Cowart on Q3 2019 Results - Earnings Call Transcript

Vertex Pharmaceuticals is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Moving Average Crossover Alert: Vertex Pharmaceuticals

This biotech stock gives investors upside to cutting-edge non-opioid pain management with a trusty revenue stream from its legacy suite of treatments for cystic fibrosis.

Why the Opioid Crisis Makes Vertex Pharmaceuticals a Buy

Vertex (VRTX) encourages investors with better-than-expected earnings in Q3. However, the top line misses the mark.

Vertex (VRTX) Q3 Earnings Beat, Revenues Lag Estimates

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) issued its third quarter results after the closing bell on Wednesday.

Vertex Pharmaceuticals Posts Strong 3rd-Quarter Revenue Growth

Intuitive Surgical

These titans of the healthcare sector sport virtual monopolies in their core markets.

2 Top Healthcare Stocks Every Investor Should Own

Will Vertex Pharmaceuticals Continue to Surge Higher?

Vertex Pharmaceuticals Incorporated (VRTX) CEO Jeff Leiden on Q3 2019 Results - Earnings Call Transcript

Vertex (VRTX) delivered earnings and revenue surprises of 7.89% and -0.25%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Vertex Pharmaceuticals (VRTX) Beats Q3 Earnings Estimates

Vertex earnings of $1.23 per share, minus some items, beat estimates Wednesday. But $949.8 million in sales lagged narrowly.

The Top-Rated Biotech Stock Just Reported A Mixed Third Quarter

Vertex Energy (VTNR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Vertex Energy (VTNR) to Report Q3 Results: Wall Street Expects Earnings Growth

Boot Barn Hlds

Columbia Sportswear Company

Spotify

Upland Software

5 top-ranked stocks likely to beat on earnings are great investment picks for stellar gains.

Looking for an Earnings Beat? 5 Top Picks

What should investors think of this piece of news?

News for Vertex Pharmaceuticals Stock (VRTX)